

Comprehensive analysis of the effects of the cuprotosisassociated gene *SLC31A1* on patient prognosis and tumor microenvironment in human cancer

Guiqian Zhang^{1,2,3,4#}, Ning Wang^{1#}, Shixun Ma^{2,3,4#}, Pengxian Tao^{2,3,4}, Hui Cai^{2,3,4}

¹The First Clinical Medical College of Gansu University of Chinese Medicine (Gansu Provincial Hospital), Lanzhou, China; ²General Surgery, Clinical Medical Center, Gansu Provincial Hospital, Lanzhou, China; ³Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou, China; ⁴NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumors, Gansu Provincial Hospital, Lanzhou, China

Contributions: (I) Conception and design: G Zhang, N Wang, H Cai; (II) Administrative support: P Tao, H Cai; (III) Provision of study materials or patients: S Ma; (IV) Collection and assembly of data: G Zhang, N Wang, S Ma; (V) Data analysis and interpretation: G Zhang, P Tao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

[#]These authors contributed equally to this work as co-first authors.

Correspondence to: Pengxian Tao, MD; Hui Cai, MD. General Surgery, Clinical Medical Center, Gansu Provincial Hospital, 204 Donggang West Road, Chengguan District, Lanzhou 730000, China; Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, Gansu Provincial Hospital, Lanzhou, China; NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumors, Gansu Provincial Hospital, Lanzhou, China. Email: taopx2017@163.com; caialonteam@163.com.

Background: Solute carrier family 31 (copper transporter), member 1 (*SLC31A1*) is a key factor in maintaining intracellular copper concentration and an important factor affecting cancer energy metabolism. Therefore, exploring the potential biological function and value of *SLC31A1* could provide a new direction for the targeted therapy of tumors.

Methods: This study assessed gene expression levels, survival, clinicopathology, gene mutations, methylation levels, the tumor mutational burden (TMB), microsatellite instability (MSI), and the immune cell infiltration of *SLC31A1* in pan-cancer using the Tumor Immune Estimation Resource 2.0 (TIMER2.0), Gene Expression Profiling Interactive Analysis (GEPIA), University of Alabama at Birmingham CANcer (UALCAN) data analysis portal, and cBioPortal databases. To further understand the potential biological mechanisms of *SLC31A1* in different cancers, single-cell level sequencing and a Gene Ontology/Kyoto Encyclopedia of Genes and Genomes (GO/KEGG) enrichment analysis of *SLC31A1* were also performed. Finally, real-time quantitative polymerase chain reaction (RT-qPCR) and western blotting (WB) were used to validate the expression of *SLC31A1* in cancers, such as gastric cancer.

Results: *SLC31A1* was expressed in most cancer tissues. In kidney renal clear cell carcinoma (KIRC), the high expression of *SLC31A1* was associated with good overall survival (OS), while in adrenocortical carcinoma (ACC), breast invasive carcinoma (BRCA), lower grade glioma (LGG), mesothelioma (MESO), and skin cutaneous melanoma (SKCM), the low expression of *SLC31A1* was associated with good OS. The highest frequency of *SLC31A1* amplification was observed in ACC. In addition, missense mutations accounted for a major portion of the mutation types. The truncation mutation S105Y may be a putative cancer driver. *SLC31A1* affected methylation levels in cancer and was associated with the TMB, MSI, and the level of infiltration of various immune cells. Additionally, the single-cell sequencing results showed that *SLC31A1* was associated with multiple biological functions in cancer. Finally, the *SLC31A1* enrichment analysis revealed that the *SLC31A1*-related genes were mainly enriched in the mitochondrial matrix and envelope vesicles. The RT-qPCR and WB results were consistent with the predicted results.

Conclusions: *SLC31A1* may be a potential target related to cancer energy metabolism and may have prognostic value.

Keywords: Cuprotosis; solute carrier family 31 (copper transporter), member 1 (*SLC31A1*); human cancer; prognosis; tumor microenvironment (TME)

Submitted Jul 25, 2023. Accepted for publication Nov 21, 2023. Published online Feb 28, 2024. doi: 10.21037/tcr-23-1308

View this article at: https://dx.doi.org/10.21037/tcr-23-1308

Introduction

Cancer is the leading cause of death worldwide and is a major public health issue (1,2). The incidence of cancer and cancer-related mortality rates are increasing rapidly worldwide due to aging and growing populations (3). Cancer is described by the histopathological, genomic, and transcriptomic heterogeneity of the tumor, and its tissue microenvironment. Cancer heterogeneity results in changes in patient outcomes (4). Histopathology biomarkers can be used to diagnose cancer; however, most histopathology biomarkers are based solely on the morphology and location of tumor cells, and a fine-grained understanding of how the spatial organization of stromal, tumor, and immune cells in the tumor microenvironment (TME) contributes to patient risk is lacking (5-7).

In studying the process of cell death carrying copper ions, Golub's team identified a new mode of cell death involving copper ions in cells that depends on and is regulated by copper ions, called cuprotosis (8). The mechanism of copper death involves copper ions binding directly to the lipid acylated components of the tricarboxylic acid cycle, which leads to the abnormal aggregation of fatty acylated proteins and the loss of iron-sulfur cluster proteins, which in turn leads to cell death mediated by a proteotoxic stress response (9).

Highlight box

Key findings

• Cuprotosis-associated gene solute carrier family 31 (copper transporter), member 1 (*SLC31A1*) affects patient prognosis and the immune microenvironment in human cancer.

What is known, and what is new?

- *SLC31A1* is responsible for copper ion transport in cuprotosis and is a key molecule in the development of cuprotosis.
- SLC31A1 is involved in regulating the prognosis of human cancer and is associated with tumor immunity.

What is the implication, and what should change now?

• SLC31A1 may be a potential tumor-associated biomarker.

Interestingly, solute carrier family 31 (copper transporter), member 1 (SLC31A1) is also a cuprotosisassociated gene. The human body contains the following two copper transporter (CTR) family proteins: SLC31A1 (CTR1) and SLC31A2 (CTR2) (10). SLC31A1 is a key residue in the highly conserved C-terminal HCH190 triplet for cell membrane cystine 189 (Cys189) and copper uptake, as in Methionine 154 (Met-154) (11-13). The main role of SLC31A1 is to transport cytosolic copper (14). SLC31A1 is engaged in the cuprum (Cu) access-dependent activation of mitogen-activated protein kinase signaling (15), which is induced by growth factors, such as the fibroblast growth factor and insulin, and the activation of Cu enzymes, including lysine oxidase (16-18). SLC31A2 is predominantly located intracellularly (19) and unlike SLC31A1, the expression level of human SLC31A1 does not result in any significant changes in cellular copper metabolism (20). SLC31A1P1 has been identified as a processing gene highly homologous to SLC31A1 (21).

In this study, we investigated the regulatory function of SLC31A1 in various cancers through a series of bioinformatics online databases. We also compared the differential expression of SLC31A1 in tumor tissues and their paracancerous tissues. In addition, patient survival and methylation levels, and their role in immune regulation were also evaluated in this study. The results suggest that SLC31A1 is closely related to tumor pathogenesis and the immune response. Finally, the results were further validated by real-time quantitative polymerase chain reaction (RT-qPCR) and western blotting (WB). The objective of this study was to identify potential targets for cancer therapy by analyzing the expression prognosis and immunity of SLC31A1 in pan-cancer, building upon previous research. The findings may provide novel insights into the molecular mechanisms of cancer and facilitate personalized treatments for pan-cancer patients. The entire study flow is shown in Figure 1. We present this article in accordance with the MDAR reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1308/rc).



Figure 1 Overview of the experiments. *SLC31A1*, solute carrier family 31 (copper transporter), member 1; RT-qPCR, real-time quantitative polymerase chain reaction; WB, western blotting.

Methods

Cell culture

Cells for experiments were obtained from the Cell Resource Center of the Chinese Academy of Sciences (Shanghai, China). The cells were cultured in Roswell Park Memorial Institute-1640 (RPMI-1640), containing 10% fetal bovine serum, 100 units/mL of penicillin, and 100 µg/mL of streptomycin, and placed in a 37 °C, 5% carbon dioxide incubator.

RT-qPCR

Total RNA was extracted separately from the cells using the Trizol method, and the purified RNA was reverse-transcribed into a complementary DNA template using a reverse transcription kit, after which RT-qPCR was performed on the target genes using PCR optics, and finally the relative expression of *SLC31A1* was analyzed using the $2^{-\Delta\Delta Ct}$ method and normalized with reference to glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*). The *SLC31A1*

 Table 1 Full names and abbreviations of the 33 cancers in the TCGA database

Abbreviations	Full names
ACC	Adrenocortical carcinoma
BLCA	Bladder urothelial carcinoma
BRCA	Breast invasive carcinoma
CESC	Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL	Cholangiocarcinoma
COAD	Colon adenocarcinoma
DLBC	Lymphoid neoplasm diffuse large B-cell lymphoma
ESCA	Esophageal carcinoma
GBM	Glioblastoma multiforme
HNSC	Head and neck squamous cell carcinoma
KICH	Kidney chromophobe
KIRC	Kidney renal clear cell carcinoma
KIRP	Kidney renal papillary cell carcinoma
LAML	Acute myeloid leukemia
LGG	Lower grade glioma
LIHC	Liver hepatocellular carcinoma
LUAD	Lung adenocarcinoma
LUSC	Lung squamous cell carcinoma
MESO	Mesothelioma
OV	Ovarian serous cystadenocarcinoma
PAAD	Pancreatic adenocarcinoma
PCPG	Pheochromocytoma and paraganglioma
PRAD	Prostate adenocarcinoma
READ	Rectum adenocarcinoma
SARC	Sarcoma
SKCM	Skin cutaneous melanoma
STAD	Stomach adenocarcinoma
TGCT	Testicular germ cell tumor
THCA	Thyroid carcinoma
THYM	Thymoma
UCEC	Uterine corpus endometrial carcinoma
UCS	Uterine carcinosarcoma
UVM	Uveal melanoma

TCGA, The Cancer Genome Atlas.

primers were designed and synthesized by Bioengineering (Shanghai, China). The forward primer for *SLC31A1* was: 5'-GTAAGTCACAAGTCAGCATTCG-3'; the reverse primer was: 5'-CAACAGTTTTGTGTGTGTCTCCAT-3'; and the *GAPDH* forward primer was: 5'-GGAAGCTTG TCATCAATGGAAATC-3', reverse primer 5'-TGAT GACCCTTGGCTCCC-3'.

WB

The liver cancer cells, other cancer cells, and normal cells underwent protein extraction. The separation process involved the use of reduced sodium dodecyl sulfatepolyacrylamide gel electrophoresis, followed by the transfer of the separated components onto polyvinylidene fluoride membranes. Subsequently, the immunoblot technique was employed for the analysis. To detect the target proteins, rabbit-horseradish peroxidase (HRP) and mouse-HRP were employed as secondary antibodies. The gray values of the protein bands were quantitatively assessed using Image J software (*, P<0.05; **, P<0.01; ****, P<0.001; *****, P<0.0001).

Differential expression analysis

The Tumor Immune Estimation Resource 2.0 (TIMER2.0) (http://timer.cistrome.org/) database was used to analyze the differential expression of SLC31A1 in different cancer tissues and normal tissues. Additionally, the Gene Expression Profiling Interactive Analysis (GEPIA) (http:// gepia.cancer-pku.cn) and GEPIA2.0 (http://gepia2. cancer-pku.cn/#index) databases were used to assess the differential expression of SLC31A1 in 33 cancers with corresponding pan-cancer tissues, and pan-cancer correlation with SLC31A1. The University of Alabama at Birmingham CANcer (UALCAN) (http://ualcan. path.uab.edu/index.html) database was used to assess the methylation levels and protein expression levels of SLC31A1 in pan-cancer based on The Cancer Genome Atlas (TCGA) database samples. The Human Protein Atlas (HPA) (https://www.proteinatlas.org) database was used to present staining visualization to reflect the protein levels of SLC31A1 in normal tissues and corresponding cancer tissues (the screening criteria were moderate or high staining intensity, and a cell count $\geq 25-75\%$). The full names and abbreviations of the pan-cancers are shown in Table 1.

718

Clinicopathological correlation analysis

The R packages "limma" and "Nagpur" were used for the clinicopathological related studies. TCGA and the genotype-tissue expression (GTEx) RNA-sequencing data were analyzed and visualized using the R packages "pROC" and "ggplot2". Xiantao Academic (https://www. xiantao.love/) was used to obtain the area under the receiver operating characteristic (ROC) curve (AUC) to determine diagnosis and prognosis.

Genetic alterations and prognostic analysis

We assessed the genetic alterations of the *SLC31A1* gene, including missense mutations, deletions, and splicing, in different cancers using the cBioPortal (https://www. cbioportal.org/) database. Survival information data for each sample were retrieved and downloaded from the TCGA database. The OS, disease-specific survival (DSS), diseasefree survival (DFS), and progression-free survival (PFS) of the cancer patients were analyzed using a Cox regression analysis. In addition, the GEPIA2.0 database was used to analyze the prognosis of *SLC31A1* gene expression in different cancers, including OS and recurrence-free survival (RFS).

TME, tumor mutational burden (TMB), microsatellite instability (MSI), and drug sensitivity

The R packages "ggplot2", "ggpubr", and "ggExtra" were used to analyze the correlation between SLC31A1 expression and the TME (P<0.001 was set as the cutoff value). Correlations between the TMB and MSI and SLC31A1 expression were calculated using the Spearman method. The R package "fmsb" was used for image visualization. NCI-60 compound activity data and RNA-sequencing expression profiles were downloaded from CellMinerTM to analyze the drug sensitivity of *SLC31A1* in pan-cancer (https://ngdc.cncb.ac.cn/databasecommons/ database/id/5025). Food and drug administration (FDA)-approved drugs or drugs in clinical trials were selected for the analysis. The visualization was performed using the R packages "impute", "limma", "ggplot2", and "ggpubr" (*, P<0.05; **, P<0.01; ***, P<0.001).

Immune infiltration analysis

We used the TIMER2.0 database to explore the relationship between *SLC31A1* gene expression and the immune

infiltrating cells.

Single-cell sequencing data analysis

The different biological functions of cancer cells in multiple cancers were analyzed at the single-cell level using the single-cell sequencing platform CancerSEA (http://biocc.hrbmu.edu.cn/CancerSEA/) database. Data on the correlation between *SLC31A1* expression and different tumor functional states were downloaded from the CancerSEA database, and correlation heat maps were created using the Xiantao Academic Online website. t-distributed stochastic neighbor embedding (t-SNE) plots from the CancerSEA database were used to identify *SLC31A1* expression in individual cancers.

Enrichment analysis

The SLC31A1 protein co-expression network was analyzed using the BioGRID database (https://thebiogrid.org/). The top 100 *SLC31A1*-related genes in pan-cancer were obtained using the GEPIA2.0 database. The association heat map between *SLC31A1* and its related genes in pancancer was generated using the TIMER2.0 database. In addition, a Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of *SLC31A1*-related genes was conducted using Xiantao Academic.

Statistical analysis

The differences between *SLC31A1* expression and prognosis (OS and RFS) in different cancer patients were obtained from the GEPIA 2.0 database. In addition, a *t*-test, Cox regression analysis, and linear regression analysis were used to compare the differences between different groups, and the data are expressed as the mean \pm standard deviation. A P value <0.05 was considered statistically significant.

Results

The expression levels of SLC31A1 in pan-cancer

The expression profile of *SLC31A1* was explored using the TIMER2.0, GEPIA2.0, and UALCAN platforms. First, we used the TIMER2.0 platform to evaluate the expression profile of *SLC31A1* in tumor tissues and normal tissues. We found that *SLC31A1* expression was up-regulated in a portion of cancers, such as bladder urothelial carcinoma (BLCA), BRCA, cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), pheochromocytoma and paraganglioma (PCPG), stomach adenocarcinoma (STAD), and uterine corpus endometrial carcinoma (UCEC). Conversely, *SLC31A1* expression was down-regulated in another fraction of cancers, such as cholangiocarcinoma (CHOL), KIRC, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), prostate adenocarcinoma (PRAD), and thyroid carcinoma (THCA) (*Figure 2A*).

We also analyzed the protein expression of *SLC31A1* using the UALCAN platform. The results showed that the SLC31A1 protein was highly expressed in GBM and lowly expressed in LIHC (*Figure 2B*). Since the TIMER2.0 database does not contain the paraneoplastic tissues data of several cancers, we also used GEPIA2.0 to explore the *SLC31A1* expression levels between these tumors and the corresponding normal tissues. The results showed that *SLC31A1* was highly expressed in colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), GBM, LGG, pancreatic adenocarcinoma (READ), STAD, and UCEC, and lowly expressed only in CHOL and acute myeloid leukemia (LAML) (*Figure 2C*).

Additionally, we analyzed the correlation between *SLC31A1* expression and pathological stages using the GEPIA 2.0 database. The results showed that *SLC31A1* expression was closely correlated with the stage of patients with ACC, KIRC, ovarian serous cystadenocarcinoma (OV), and THCA. In ACC, *SLC31A1* had the highest expression in stage IV and the lowest expression in stage I. In KIRC, *SLC31A1* had the highest expression in stage I and the lowest expression in stage I and the lowest expression in stage II and the lowest expression in stage II and the lowest expression in stage II and the lowest expression in stage IV (*Figure 2D*).

We then selected cancer types with differential expression of SLC31A1 in the UALCAN database and visualized their protein expression levels using the HPA database. The results showed that *SLC31A1* expression was up-regulated in BRCA, STAD, and UCEC, and down-regulated in LIHC. *SLC31A1* showed moderate or high staining in BRCA, STAD, and UCEC tumor tissues with $\geq 25-75\%$ stained cells, while its corresponding normal tissues were moderately stained or unstained. Conversely, the LIHC tumor tissues were moderately stained or unstained, while its corresponding normal tissues were moderately or highly stained. The differential expression and protein levels differential expression of the above results were consistent (*Figure 3*). The differential expression results for the other cancers with opposite protein-level expression are shown in Figure S1.

The survival analysis of SLC31A1 in cancer

The GEPIA2.0 database was used to study the prognostic value of *SLC31A1* expression in cancer. We divided the patients into a high expression group and a low expression group. In KIRC, high *SLC31A1* expression was associated with good OS, and in ACC, BRCA, LGG, MESO, and SKCM, low *SLC31A1* expression was associated with good OS (*Figure 4A*). Further, we found that high expression levels of *SLC31A1* were associated with good DFS in KIRC and STAD, and low expression levels of *SLC31A1* were associated with good DFS in *KIRC and MESO* (*Figure 4B*).

Correlation of SLC31A1 expression with clinicopathology

As Figure 5A shows, SLC31A1 was highly expressed in ACC stage III-IV patients and lowly expressed in stage I-II patients. SLC31A1 was highly expressed in testicular germ cell tumors (TGCTs) stage II-III patients and lowly expressed in stage I patients. Conversely, SLC31A1 was highly expressed in KIRC and THCA stage I-II patients and lowly expressed in stage III-IV patients. In addition, SLC31A1 expression was strongly correlated with the age of ESCA, OV, sarcoma (SARC), STAD, and UCEC patients. Of these, SLC31A1 was highly expressed in OV and UCEC patients up to and including 65 years of age, while it was highly expressed in ESCA, SARC and STAD patients over 65 years of age. Finally, we found that SLC31A1 was highly expressed in female patients with ACC, BRCA, kidney chromophobe (KICH), KIRC, and KIRP. Next, ROC curves were used to verify the diagnostic value of SLC31A1 for different cancers. As Figure 5B shows, SLC31A1 had more than moderate diagnostic accuracy (AUCs above 0.69 and even 0.8) for a variety of tumors including BRCA, CESC, and CHOL. In conclusion, the ROC curve analysis showed that SLC31A1 is a valuable diagnostic biomarker.

Genetic alterations of SLC31A1 in pan-cancer

We used the cBioPortal tool to study *SLC31A1* gene alterations in pan-cancer. As *Figure 6A* shows, *SLC31A1*

Zhang et al. Cuprotosis-associated gene SLC31A1



Figure 2 Expression levels of *SLC31A1* in pan-cancer. (A) Expression of *SLC31A1* in cancer versus normal tissues in the TIMER2.0 database. (B) Protein levels of *SLC31A1* in tumor and normal tissues from the UALCAN database. (C) Expression of *SLC31A1* in cancer and normal paracancerous tissues in the GEPIA2.0 database. (D) Correlation between *SLC31A1* and cancer pathological staging based on GEPIA 2.0 data. *, P<0.05; **, P<0.01; ***, P<0.0001. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; DAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; TPM, transcripts per million; CPTAC, Clinical Proteomic Tumor Analysis Consortium; TIMER, Tumor Immune Estimation Resource; UALCAN, University of Alabama at Birmingham CANcer; GEPIA, Gene Expression Profiling Interactive Analysis.



Figure 3 *SLC31A1* expression in the UACLAN and HPA databases. Immunohistochemistry x40 images are presented. BRCA (normal breast: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/breast#img, BRCA: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/breast#img, BRCA: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/liver#img, LIHC: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/pathology/liver+cancer#img); STAD (normal stomach: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/stomach#img, STAD: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/stomach#img, STAD: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/stomach#img, STAD: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/stomach#img, STAD: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/stomach#img, STAD: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/tissue/stomach#img, STAD: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/pathology/stomach+cancer#img); UCEC (normal endometrioid: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/pathology/endometrium#img, UCEC: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/pathology/endometrium#img, UCEC: https://www.proteinatlas.org/ENSG00000136868-SLC31A1/pathology/endometrial+cancer#img). *, P<0.05; ****, P<0.0001. TCGA, The Cancer Genome Atlas; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; BRCA, breast invasive carcinoma; LIHC, liver hepatocellular carcinoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; UALCAN, University of Alabama at Birmingham CANcer; HPA, Human Protein Atlas.

Zhang et al. Cuprotosis-associated gene SLC31A1



Figure 4 Survival analysis of *SLC31A1* in pan-cancer. (A) OS. (B) RFS. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; HR, hazard ratio; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; OS, overall survival; RFS, recurrence-free survival.



Figure 5 Relationship between *SLC31A1* and clinicopathology of patients with pan-cancer. (A) *SLC31A1* was correlated with the clinical stage, age, and sex of patients. (B) ROC curve analysis of the diagnostic value of *SLC31A1* in pan-cancer. *, P<0.05; **, P<0.01; ***, P<0.001. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; PAAD, lung adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; AUC, area under the receiver operating characteristic curve; CI, confidence interval; FPR, false positive rate; TPR, ture positive rate; ROC, receiver operating characteristic.



Figure 6 Mutation frequency of SLC31A1 in pan-cancer. (A) Mutation types. (B) Mutation frequencies. (C) 3D structure of S105Y. CNA, copy-number alterations; SLC31A1, solute carrier family 31 (copper transporter), member 1; TCGA, The Cancer Genome Atlas; SV, synaptic vesicle.

had the highest amplification frequency in ACC, the highest mutation frequency in UCEC, the highest deep deletion frequency in THCA, and the highest multiple alteration frequency in BRCA. In addition, we explored the mutation types and mutation sites in the *SLC31A1* sequence. The mutation types of *SLC31A1* mainly included missense mutations, truncation mutations, splice mutations, and synaptic vesicle (SV)/fusion. In addition, missense mutations accounted for a portion of the mutation types. The truncating mutation, S105Y, may be a putative cancer driver (*Figure 6B*). We further derived the three-dimensional (3D) structure of S105Y (*Figure 6C*).

Next, we used forest plots to show the association

between *SLC31A1* genetic alterations and patient prognosis. *SLC31A1* genetic alterations were associated with OS in patients with ACC, BLCA, BRCA, KIRC, LGG, MESO, and SKCM. Among them, *SLC31A1* genetic alterations were positively correlated with OS in ACC, BLCA, BRCA, LGG, MESO, and SKCM patients, and *SLC31A1* genetic alterations were negatively correlated with OS in KIRC patients (*Figure 7A*). *SLC31A1* genetic alterations were associated with PFS in ACC, BLCA, BRCA, CESC, KIRC, LGG, MESO, READ, and uveal melanoma (UVM) patients. Among them, *SLC31A1* genetic alterations were positively correlated with PFS in ACC, BLCA, BRCA, CESC, CESC, LGG, MESO, and UVM patients, and *SLC31A1*

						0		
Cancer	P value	Hazard Ratio(95% CI)			Cancer	P value	Hazard Ratio(95% CI)	
ACC	0.0005	4.77585(1.99281,11.44552)	+ −1		ACC	⊲0.0001	4.35661(2.1808,8.70328)	
BLCA	0.0199	1.42309(1.05731,1.91543)	t		BLCA	0.0155	1.45179(1.07352,1.96334)	*
BRCA	0.0024	1.6528(1.19422,2.28749)	•		BRCA	0.0362	1.41885(1.02268,1.96849)	-
ESC	0.2862	1.28874(0.80854,2.05414)	•		CESC	0.0447	1.62543(1.01155,2.61187)	
CHOL	0.4891	0.71547(0.27706,1.84758)	•		CHOL	0.3787	0.66883(0.27314,1.63777)	H + -1
COAD	0.4519	0.86106(0.58314,1.27143)	•		COAD	0.2045	0.7934(0.55493,1.13436)	
DLBC	0.7393	0.79001(0.19707,3.16707)	+		DLBC	0.534	0.68562(0.20871,2.25232)	•
ESCA	0.3309	0.78374(0.47955,1.28088)	•		ESCA	0.4297	0.83764(0.53961,1.30028)	+
GBM	0.8286	1.04159(0.72032,1.50614)	•		GBM	0.9768	0.9946(0.69091,1.43179)	+
HNSC	0.4648	1.10463(0.84596,1.44238)	•		HNSC	0.9194	1.01469(0.76489,1.34608)	+
KICH	0.3684	1.89175(0.47165,7.58772)	H		KICH	0.3417	1.81669(0.53067,6.21924)	•
KIRC	0.0001	0.53366(0.39134,0.72774)	•		KIRC	<0.0001	0.4281(0.30638,0.59817)	•
KIRP	0.2095	0.67357(0.36337,1.24855)	+		KIRP	0.5392	1.17969(0.69608,1.99928)	+
LAML	0.1046	1.41967(0.92985,2.16752)	•		LGG	0.0162	1.42806(1.06817,1.9092)	1 41
LGG	0.0008	1.93279(1.31737,2.83571)	•		LIHC	0.6793	1.06379(0.7935,1.42615)	+
LIHC	0.0675	0.72399(0.51214,1.02347)	•		LUAD	0.4551	0.90095(0.68524,1.18457)	+
LUAD	0.6499	0.93494(0.69924, 1.25008)	•		LUSC	0.9159	1.01768(0.73517,1.40874)	+
LUSC	0.8976	1.01794(0.77632,1.33478)	•		MESO	0.0084	2.06416(1.20427,3.53803)	
MESO	0.0001	2.73985(1.68173,4.46371)	•		OV	0.1843	0.85073(0.67012,1.08001)	
OV	0.3067	1.14456(0.88351,1.48274)	•		PAAD	0.2388	1.26293(0.85643,1.86239)	1 4 -1
PAAD	0.4057	1.19245(0.78753,1.80556)	+		PCPG	0.8699	0.93014(0.39093,2.2131)	+
PCPG	0.2621	2.56316(0.49465,13.28159)	⊷ 1		PRAD	0.267	0.79409(0.52854,1.19306)	+
PRAD	0.7733	0.82671(0.22644,3.01818)	+		READ	0.0352	0.47472(0.23728,0.94975)	+
READ	0.3530	0.6842(0.30715,1.52409)	+		SARC	0.5449	1.10842(0.79432,1.54673)	+
SARC	0.2373	1.26927(0.85471,1.8849)	•		SKCM	0.595	1.06276(0.84915,1.33012)	+
SKCM	0.0054	1.47407(1.12176,1.93702)	•		STAD	0.0599	0.71173(0.49945,1.01425)	+
STAD	0.2219	0.81497(0.5869,1.13167)	•		TGCT	0.3156	1.41677(0.71743,2.79784)	+++
THCA	0.3329	1.64991(0.59884,4.54576)	•		THCA	0.2527	0.72981(0.42543,1.25195)	14 1
THYM	0.0522	7.85815(0.98067,62.96793)	•	•	THYM	0.4714	1.37441(0.57843,3.26573)	⊢ ♦——1
UCEC	0.5513	0.88091(0.58045,1.33688)	•		UCEC	0.1978	0.79111(0.55383,1.13007)	
					UCS	0.2296	1.48744(0.7783,2.8427)	••• ••
UCS	0.1178	1.7203(0.87173,3.3949)	+		003			
UCS UVM	0.1178 0.5113 Disea	1.7203(0.87173,3.3949) 1.32008(0.57635,3.02352) 0 ISE-Specific S	197 12.5 20 30 40 50 6 Hazard Ratio	" D	UVM	0.0346 Disea	2.38828(1.06512,5.35518) 0 ase-free survi	120871 2 3 4 5 Hazard I
UCS UVM Cancer	0.1178 0.5113 Disea P value	1.7203(0.87173,3.3949) 1.32008(0.57635,3.02352) 0 ISE-SPECIFIC SI Hazard Ratio(95% CI)	197 12.5 20 30 40 50 6 Hazard Ratio	D	UVM	0.0346 Disea P value	2.38828(1.06512,5.35518) 0 ase-free survi Hazard Ratio(95% CI)	1.20871 2 3 4 5 Hazard I
UCS UVM Cancer	0.1178 0.5113 Disea P value 5c-04	1.7203(0.87173,3.3949) 1.32008(0.57635,3.02352) 0 RSE-SPECIFIC S Hazard Ratio(95% CI) 5.21193(2.04958,13.25339)	197 12.5 20 30 40 50 6 Hazard Ratio	D	UVM Cancer ACC	0.0346 Disea P value 0.2621	2.38828(1.06512,5.35518) 0 ase-free survi Hazard Ratio(95% CI) 2.02098(0.59093,6.91172)	120871 2 3 4 5 Hazard I
UCS UVM Cancer ACC BLCA	0.1178 0.5113 Disea P value 5e-04 0.0695	1.7203(0.87173,3,3949) 1.32008(0.57635,3,02352) 0 ISSE-SPECIFIC SI Hazard Ratio(95% CI) 5.21193(2,04958,13,25339) 1.39672(0.97368,2,00357)	197 125 20 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA	0.0346 Disea P value 0.2621 0.6483	2.38828(1.06512.5.35518) 0 ase-free survi Hazard Ratio(95% CI) 2.02098(0.59093.6.91172) 1.17915(0.58087.2.39366)	ival
UCS UVM Cancer ACC BLCA BRCA	0.1178 0.5113 Disea P value 5e-04 0.0695 0.0673	1.720340 87173,3.3949) 1.32008(0.57635.3.02352) 0 ISE-Specific S Hazard Ratio(95% CI) 5.21193(204958,13.25359) 1.39672(0.97368.200557) 1.396710(7.23654)	197 12.5 20 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA	0.0346 Disea P value 0.2621 0.6483 0.7707	2.38828(1.06512.5.35518) 0 ase-free survi Hazard Ratio(95% Cl) 2.02098(0.5903.6.91172) 1.17915(0.58087.2.39366) 1.05572(0.69464.1.6350)	120871 2 3 4 5 Hazard I
UCS UVM Cancer ACC BLCA BRCA CESC	0.1178 0.5113 Disea P value 5e-04 0.0695 0.0673 0.2765	1.720040 87173,33949) 1.320080,057635,302352) 0 ISE-Specific S Hazard Ratio95% CD 5.21193(204958,13,2539) 1.39672(097167,2,30564) 1.49677(097167,2,30564) 1.4952(7,08512,22933)	197 12:20 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709	2.38828(1.06512.5.35518) 0 BSE-free Survi Hazard Ratio(95% Ct) 1.07915(0.58087.2.39360) 1.05672(0.69464.1.6350)) 1.25108(0.5766.2.71473)	ival
UCS UVM Cancer ACC BLCA BRCA CESC CHOL	0.1178 0.5113 Disea P value 5c-04 0.0695 0.0673 0.2765 0.3801	1.720.00, 87173, 3.3949) 1.320080, 57635, 3.02352) 0 ISE-Specific S Hazard Ratio95% CI) 5.21193(2.04958, 1.32539) 1.39672(0.97368, 2.00357) 1.49677(0.97167, 2.30664) 0.63597(0.20421, 7.642)	197 12.520 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CHOL	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770	2.38828(1.06512.5.35518) 0 BSE-free Survi Hzard Ratio(95% CI) 2.02098(0.59093.6.91172) 1.17915(0.58087.2.39366) 1.055702(0.69464.1.63501) 1.25708(0.57562.2.71473) 0.90467(0.25444.3.21661)	ival
UCS UVM Cancer ACC BLCA BRCA CESC CHOL COAD	0.1178 0.5113 Disea P value 5e-04 0.0695 0.0673 0.2765 0.3801 0.2968	1.720.00.87173,3.3499) 1.32008(0.576.05.3.02352) 0 See-Specific Si Internet Ratio(95% C1) 1.997(20.97362,20057) 1.997(20.97362,20057) 1.49677(0.971672,30564) 1.34552(0.78851,22933) 0.63509(0.23042,1.75042) 0.7685(0.46881,24005)	1977 12:520 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CHOL COAD	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.8770	2.38828(1.06512.5.35518) 0 Base-free Survi 2.02998(0.5993.6.9172) 1.17915(0.58087.2.9366) 1.05572(0.69464.1.6350) 1.25108(0.57656.2.7147) 0.90467(0.25444.3.2166)) 0.90467(0.25444.3.2166))	ival
Cancer ACC BLCA BRCA CESC CHOL COAD DLBC	0.1178 0.5113 Disea P value 5c-04 0.0695 0.0673 0.2765 0.3801 0.2968 0.8203	1.720.00, 871 73, 3.2489) 1.32008(0.576.05, 3.02352) Idea of the state of the st	197 125 20 40 50 6 Hazard Ratio	, D	Cancer ACC BLCA BRCA CESC CHOL COAD DLBC	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.2308 0.5536	2.38828(1.06512.5.35518) 0 Bazerd Ratio(95% C1) 1.079150(5.50872.39360) 1.05672(0.69464.1.6350) 1.25108(0.57662.57147) 0.90467(0.25464.1.21660) 0.90467(0.25464.1.21.38690) 0.48521(0.04254.5.57917)	L20871 2 3 4 5 Hazard I
UCS UVM Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA	0.1178 0.5113 Disea P value 5e-04 0.0695 0.0673 0.2765 0.3801 0.2968 0.8203 0.2282	1.220(0,57173.3.989) 1.3200(0,570.5.1,0235) 1.3200(0,570.5.1,0235) 1.300(0,570.5.1,0235) 1.300(0,570.5,0235) 1.4007(0,071.07.2,056) 1.4057(0,071.07.2,056) 1.4057(0,071.07.2,056) 0.3550(0,242,1,7542) 0.7566(0,44383,1,2005) 0.7566(0,1120,5,642) 0.756(0,1120,5,642)	1197 125 29 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.2308 0.5536 0.4596	23882(1.065125.3551)) 0 RESE-FECE SULVIV Hazard Ratio(95% CI) 1.0795(0.58072.39056) 1.05970.0446.1350) 1.259808.756.056.211473) 0.95970.0257(2.13609) 0.4825(10.0423.53791) 0.4825(10.0423.53791)	I 20871 2 3 4 5 Hazard I
Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA GBM	0.1178 0.5113 P value 5c-04 0.0695 0.0673 0.2765 0.3801 0.2968 0.8203 0.2282 0.4261	1/200(037133.3949) 1/32000(037053.02525) (0 (0 (0 (0 (0 (0 (0 (0 (0 (0	127 12.5 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA IINSC	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.2308 0.5536 0.4596 0.7419	23882(10.06125.34511) 0 3280-Éftee Suttive 1208760 ,95003,61172) 1.07150,95002,54012,540 1.050760,92441,3501) 0.0507760,92441,35101) 0.9507760,92441,35101) 0.4521(0.0425,530717) 0.4521(0.0425,530717) 0.21210,03062,13750)	ival
Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA GBM HNSC	0.1178 0.5113 P value 5e-04 0.0695 0.0673 0.2765 0.3801 0.2905 0.3203 0.2282 0.4261 0.9159	1/200(037133.3989) 1/200(03703.30252) Bazard Ratio/54 (21) S21 (962,4988,132559) 1.9972(097162.35664) 1.9972(097162.35664) 1.9972(097162.35664) 0.6975(0.21942,12981) 0.7566(0.104888,12600) 0.7566(0.1045,4542) 0.0756(0.1045,4542	1127 125 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA HNSC KIRC	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.2308 0.5536 0.4596 0.7419 0.4150	23882(10.06125.3551)) 0 Base-Free Surve Base Free Surve Base Street 1 ,250900,59003,691172) 1,251000,55062,27403) 0,509700,25441,326()) 0,509700,25441,32591() 0,82820,01403,135701) 0,82820,01403,135701) 0,82820,01403,135701)	J20871 2 3 4 5 Hazard 1
Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA GBM HNSC KICH	0.1178 0.5113 Disea P value 5c-04 0.0695 0.0673 0.2765 0.3801 0.2968 0.8203 0.2282 0.4261 0.9159 0.2853	1.2200(0.57133.3496) 1.3200(0.57053.02252) 0 see-specific s 1.000(0.57053.02252) 1.000(0.5705.02252) 1.000(0.00051.0255) 1.00070(0.20550 1.00070(0.20550) 1.00070(0.20550) 0.7560(0.1120.5646) 1.00070(0.20560) 0.7560(0.1120.5646) 1.00070(0.20560) 1.1402(0.00051.2150) 1.1402(0.00051.2164) 1.0170(0.71214.14000) 1.0170(0.71214.140	197 125 20 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CHOL COAD DLBC ESCA HNSC KIRC KIRC	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.5536 0.4596 0.4596 0.7419 0.4150 0.1343	23822(106125.3551)) 0 asse-free surve harard Ratio95*4 (1) 200996-90905,6917(2) 1107105 08075,0962,7147) 1107105 08075,0962,7147) 125106,09642,31240) 0.9046702 4244,312460) 0.9046702 4246,312460) 0.9046702 42460,312460) 0.9046702 42460,3124600) 0.9046702 4246000000000000000000000000000000000	2007) 2 3 4 5 Hazard 1 Val
UCS UVM ACC BLCA BRCA CESC CHOL COAD DLBC ESCA GBM HNSC KICH KIRC	0.1178 0.5113 Disea 5 0.1178 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.5113 0.613 0.2765 0.3801 0.2968 0.8203 0.22853 =0.0001	1/200(037173.3.989) 1/320000.57053.02352) Comparing the second	U177 12.5 20 0. 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CHOL ESCA HNSC KIRC KIRC LGG	0.0346 P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.2308 0.5536 0.4596 0.4596 0.7419 0.4150 0.1343 0.1802	23882(10.0612.5.3551)) 0 Base-Éfree Suttry International State International State	A A A A A A A A A A A A A A A A A A A
UCS UVM ACC BLCA BRCA CESC CHOL BRCA CESC CHOL BRCA CESCA GBM HNSC KICH KIRC KIRP	0.1178 0.5113 Disea P value 5c-04 0.0695 0.0673 0.2765 0.3801 0.2968 0.8203 0.2282 0.4261 0.9159 0.2853 <0.0001	1/200(037173.3049) 1/200(037173.3049) 1/200(035.02552) Inzard Ratio/54 (21) S119(2,494831.53559) 1.9972(097162.35664) 1.9972(097162.35664) 0.6973(0.97162.35664) 0.6973(0.97162.35664) 0.6973(0.97162.35664) 0.6973(0.97946.12481.2609) 1.1740(2)04881.2609) 0.7566(1.1045642) 0.6993(0.9995.1241) 0.7566(1.045642) 0.6993(0.9995.1241) 0.10176(0.7212.4.10900) 2.4491(0.4756.21242.4.0900) 2.4491(0.4756.21242.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.4756.2124.4.0910) 2.4491(0.47	1197 125 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CESC CESC CESC CESC COAD DLBC ESCA HNSC KIRC KIRC KIRC KIRC LGG LIHC	0.0346 P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.2308 0.5536 0.4596 0.7419 0.4150 0.1343 0.1802 0.8574	23822(10.06125.3551)) 0 3282-FFC0E SULVIV 12020900.59000.69172) 1.1791(58.0972.39040) 1.251000.57662.71473) 0.390760.2972.4143.2140) 0.997760.2972.4143.2140) 0.997760.2972.4143.2140) 0.882540.014325.379771 0.72120.00451.814291) 0.882540.014325.379771 0.282400.014325.379771 0.282400.014325.379771 0.282400.014325.379771 0.282400.014325.329791 0.546000.82265.322279) 0.546000.82265.322279	200571 2 3 3 4 5 Hazard 1
UCS UVM ACC BLCA BRCA CESC CHOL CCAD DLBC ESCA GBM HNSC KICH KIRC LGG	0.1178 0.5113 Disea P value 5c-04 0.0005 0.3005 0.2765 0.3801 0.2965 0.3203 0.2282 0.4261 0.9159 0.2853 -40.0001 0.5953 6c-04	1.2200,037133,3496) 1.3200,0453,02250 Stear Specific S Inzard Ratio(95% C1 3.50706,2085,1230 1.3972(0.9746,20057) 1.3972(0.9746,20057) 1.3972(0.9746,20057) 1.3952(0.9746,20057) 1.3452(0.7456,20057) 0.7956(0.1120,1564) 0.7956(0.1120,1564) 0.7956(0.1120,1564) 1.9170(0.7121,214,13000) 0.9756(0.1121,214,13000) 0.9756(0.1121,214,13000) 0.9756(0.1121,214,13000) 0.9756(0.1121,214,13000) 0.9756(0.1121,214,13000) 0.9756(0.1121,214,13000) 0.9756(0.1124,124,01457) 0.91440(0.4754,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4864,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144(0.4754,216,2454) 0.9144	197 125 20 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA BRCA CESC CHOL COAD DLBC ESCA HENSC KIRC KIRP LGG LIBCG LIBCG	0.0346 Disea P value 0.2621 0.6483 0.7707 0.5709 0.8770 0.2308 0.5536 0.4596 0.7419 0.4150 0.1343 0.1802 0.8574 0.8993	23822(106125.3551)) 0 RESEVENCE 10 RESEVENCE 10 0 0 0 0 0 0 0 0 0 0 0 0 0	20071 2 3 4 5 Hazard 1
UCS UVM ACC BLCA BRCA CESC CHOL COAD DLBC ESCA GBM HNSC KICI KIRC KIRP LGG LIHC	0.1178 0.5113 P value 5c-04 0.06573 0.2765 0.3801 0.2968 0.3803 0.2282 0.4261 0.9159 0.2853 <0.001 0.2853 <0.001 0.2853 <0.001 0.2853 <0.001	1.220(0,57173.3,398) 1.32000,05705.3,02520 See_Specific S Staard Ratio (954 CH 5.2119(2,4993,1,2339) 1.9972(0,97162,33564) 1.9972(0,97162,33564) 1.9972(0,97162,33564) 1.9972(0,97162,33564) 1.9975(0,97162,33564) 1.997	1977 12:52 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA CESC CHOL COAD DLBC ESCA HNSC KIRP LGG LHC LUBC	0.0346 Disea P value 0.2621 0.6483 0.707 0.5709 0.8770 0.5336 0.4596 0.4596 0.4596 0.4190 0.1343 0.1802 0.8394 0.8993 0.5894 0.5894 0.5894	23882(10.0612.5.38518) 0 3 3 3 3 3 3 3 3 3 3 3 3 3	200571 2 3 3 4 5 Hazard 1 ival
UCS UVM ACC BLCA BRCA CESC CHOL COAD DLBC ESCA GBM HNSC KICH KIRC LIGG LIHC LUAD	0.1178 0.5113 P value 5c-04 0.0605 0.0673 0.2765 0.3801 0.2765 0.3801 0.2282 0.4261 0.9283 0.4261 0.9283 0.4261 0.9283 0.4261 0.9283 0.4261 0.9285 6-040 0.5905 6c-04 0.3574	1/200(037173.3099) 1/200(037053.02552) Inzard Ratio/54 (21) Science Section Science Section Instruct Ratio/54 (21) Instruct Ratio/54	1197 125 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA CESC CHOL COAD DLBC ESCA HINSC KIRC LGG LIRC LUAD LUSC MESO	0.0346 Disea P value 0.2621 0.6483 0.7707 0.2308 0.5536 0.4596 0.7419 0.4150 0.1343 0.1802 0.8574 0.8574 0.8933 0.7060 0.1467	23822(10.06125.3511)) 0 Carace - free Surve Data Control Data Control	ival
UCS UVM ACC BLCA BRCA CISC CIGL COAD DLBC ESCA GBM HNSC KICH KIRC KIRP LGG LIHC LUAD LUSC	0.1178 0.5113 P value P value 0.0673 0.0673 0.2765 0.0801 0.2382 0.4261 0.2382 0.4261 0.2382 0.4261 0.9199 0.2882 0.4261 0.9199 0.2883 0.2382 0.4261 0.2382 0.4261 0.2382 0.4261 0.2382 0.4261 0.2382 0.4261 0.2382 0.23	1.2200,037133,3496) 1.3200,037033,02230 Stear Speecific S Inzard Ratio(95% CL) 1.3972(0.9736,22035) 1.39772(0.9736,22035) 1.3972(0.9756,22035) 1.3972(0.9756,22035)	197 125 20 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BRCA CISC CIOL COAD DLBC ESCA HINC LIAC LIAC LUAD LUSC MESO OV	0.0346 P value 0.2621 0.6483 0.7707 0.2308 0.5536 0.5536 0.5536 0.5536 0.5459 0.2419 0.4150 0.1343 0.1367 0.2085 0.3660 0.1467	23822(10.05125.3513)) 0 2009	ival
UCS UVM ACC BLCA BRCA BRCA CESC CIOL COAD DLBC ESCA GBM HNSC KIRP LGG LIHC LIGG LIHC LIGG LIGC LGAC MESO	0.1178 0.5113 P valued 5-04 0.0695 0.0695 0.0695 0.0695 0.0695 0.0695 0.0266 0.0260 0.0280 0.0280 0.0280 0.0280 0.0280 0.0280 0.0280 0.05000 0.05000 0.05000 0.0500000000	1.220(0,57173.3,398) 1.32000,0.57053.02325) Inarat Raio(955 c1) SCHOOLS 2017 Inarat Raio(955 c1) Inarat Raio(955 c1) Inara	1977 12:52 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BLCA BRCA CISC CIOL COAD DLIC COAD DLIC LURC LURC LURC LURC LURC LURC UCC OV DLICS COAD COAD COAD COAD COAD COAD COAD COAD	0.0346 P value P value 0.2521 0.5483 0.5536 0.5709 0.5709 0.5709 0.4596 0.5419 0.4596 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4597 0.4577 0.47777 0.47777 0.47777 0.47777 0.47777 0.477777 0.4777777777777777777777777777777777777	23882(10.0612.5.3851)) 0 3 3 3 3 3 3 3 3 3 3 3 3 3	200571 2 3 3 4 5 Hazard 1 ival
UCS UVM ACC BLCA BRCA BRCA CESC CHOL CCAD DLBC ESCA GBM HNSC CSA KICH KIRC LIBC LIBC LUAD LUSC OV	0.1178 0.5113 P value 5-04 0.0695 0.0673 0.2765 0.3801 0.2968 0.3203 0.2282 0.2833 0.2282 0.2968 0.3290 0.2833 0.2995 0.2833 0.2995 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.2853 0.9199 0.9199 0.2853 0.9199 0.2853 0.9199 0.9574 0.9399	1.220(0,57173,3496) 1.3200(0,5763,30255) Inzard Ratio/54 (21) Science Section Science Section 1. 9972(0,97162,35664) 1.9972(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,97162,35664) 0.6979(0,9716,3564) 1.1742(0,3764) 1.1742(0,3	urvival	D	Cancer ACC BLCA BRCA CESC CIIOL COAD DLIC ESCA HINSC KIRC KIRC KIRC KIRC KIRC KIRC KIRC KIR	0.0346 P value 0.2621 0.4533 0.3707 0.5709 0.5709 0.5709 0.5536 0.4596 0.2388 0.5536 0.4596 0.2419 0.4596 0.4597 0.45976 0.4597 0.4597676 0.4597676 0.45976 0.45976 0.4597676 0.4597676 0.4597676 0.4597676	23822(10.05125.3513)) 0 20 20 20 20 20 20 20 20 20	Val
UCS UVM ACC BLCA CCB BLCA CCB CIGL COAD DLBC CAD DLBC CAD DLBC CAD DLBC CAD DLBC CAD DLBC CAD DLBC CAD LLC LLC LLC LLC LLC LLC CAD CAD CAD CAD CAD CAD CAD CAD CAD CA	0.1178 0.5113 0.5113 5c-04 0.0673 0.2705 0.3801 0.2705 0.3203 0.4201 0.2908 0.4201 0.0199 0.4203 0.4203 0.4203 0.4203 0.4203 0.4204 0.420000000000	1.220(0,57173.3,398) 1.32000,05705.3,02527) IDENTIFY Control State Selection State	urvival	D	Cancer ACC BLCA BRCA BRCA CESC CHOL COAD DLBC ESCA HNNC KIRP LGG LINC KIRP LGG LUSC MESO OV PAAD PCAG PRAD	0.0346 P value 0.2621 0.6483 0.7707 0.5709 0.5709 0.5709 0.5709 0.5709 0.5709 0.5709 0.4150 0.4180 0.1343 0.13802 0.8574 0.9382 0.75888 0.7588 0.7588 0.7588 0.7588 0.7588 0.7588 0.7588 0	23822(10.05125.3513)) 0 2005	val
UCS UVM ACC BLCA CESC CHOL COAD DLBC ESCA CESC CHOL ESCA GBM HINSC KICH KIRC KIRC LIBC LUAD LUSC MESO OV PAAD	0.1178 0.5113 P value P value 5 - 04 0.0695 0.2765 0.2801 0.2765 0.2801 0.2968 0.4201 0.2420 0.4201 0.2420 0.4204 0.4204 0.4204 0.4204 0.4357 0.4357 0.6624 0.4357 0.6624 0.4357 0.6624 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6625 0.6655 0.65555 0.65555 0.65555 0.655555 0.65555 0.65555 0.65555 0.65555 0.65555 0.65555555	1.220(0,57173.3,3989) 1.32000,0.57053.023250 Manard Ratio(955 C10) S. Hanard Ratio(955 C10) S. Hanard Ratio(955 C10) 1.9972(0,97162.3)5664) 1.9972(0,97162.3)5664) 1.9972(0,97162.3)5664) 0.05980,122351 0.05980,20242,13989,13741) 0.75665(1,013699,13741) 0.05980,13099,13741) 0.05980,13099,13741) 0.05980,13099,137410 0.05980,13099,137410 0.05980,13099,137410 0.05980,13099,137410 0.051440,03091,137400 0.05440(0,051871,12570) 0.05440(0,051871,12570) 0.05440(0,051871,12570) 0.05400(0,0512,15170) 0.05400(0,05	III 1977 12:52 30 40 50 6 Hazard Ratio	D	Cancer ACC BRCA BRCA BRCA CESC CIOL COAD DLIDC ESCA IINSC LUBC LUBC LUBC LUBC LUBC LUBC USC MESO OV PRAD READ READ	0.0346 P value 0.2621 0.5707 0.5707 0.5707 0.5707 0.5707 0.5707 0.5707 0.5707 0.5707 0.5536 0.4540 0.4500 0.4150 0.1467 0.5993 0.7060 0.1467 0.5993 0.7060 0.1467 0.5993	23882(10.0612.5.3351)) 3 3 3 3 3 3 3 3 3 3 3 3 3	200571 2 3 3 4 5 Hazard 1 ival
UCS UVM ACC BLCA BLCA BLCA BLCA CESC CIGL COAD DLBC ESCA GBM HNSC KICH LOBC LGG LHIC LUAD LUSC MUSC OV PAAD PCTG PAD	0.1178 0.5113 Disce P value 0.0057 0.2861 0.2765 0.3801 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3803 0.2785 0.3853 0.2853 0.2853 0.2853 0.2853 0.2853 0.2853 0.2853 0.2855 0.3857	1/200(057173.30490) 1/200(057053.02552) Inzero Residence Section 20 Sec-Specific SS Inzero Residence Section 20 S10(962,49985,135359) 1.9977(0071962,20564) 1.9977(0071962,20564) 0.69970(20162,20564) 0.69970(20162,20564) 0.69970(20162,20564) 0.69970(20162,20564) 0.69970(20162,20564) 0.49970(20162,20564) 0.49970(20162,20564) 0.49970(20162,20564) 0.49970(20162,20564) 0.49970(20162,20564) 0.89440(0.4515,21547) 0.99420(0.45171,21542) 2.51450(0.4597,21544) 1.5571(0.06452,2144,5454) 1.55	urvival	D	Cancer ACC BRCA BRCA BRCA CRC CIGC CIGC CIGC CIGC CIGC CIGC CIGC	0.0346 Disea P value 0.04 0.0483 0.707 0.5709 0.8770 0.5306 0.5336 0.5458 0.5459 0.143 0.0548 0.0449 0.143 0.0580 0.143 0.0580 0.049 0.049 0.049 0.049 0.049 0.058 0.049 0.058 0.049 0.058 0.049 0.058 0.058 0.049 0.058 0.05 0.05	23822(10.05125.3513)) 0 2009 200	ival
UCS UVM ACC BRCA BRCA BRCA CISC CIGL CIGL CIGL CIGL CIGL CIGL CIGL CIG	0.1178 0.5113 P value 5c-04 0.0695 0.3801 0.2705 0.3801 0.2282 0.3203 0.2282 0.3203 0.2282 0.3203 0.2282 0.3203 0.2282 0.3203 0.2282 0.3203 0.2282 0.3203 0.2282 0.3293 0.	1.220(0,57173.3,398) 1.32000,57653.02527) See_specific St Set Rand Raio(95* C1) 5.2119(2,4048,1,12539) 1.3957(20738,12253) 1.3957(20738,122553) 1	urvival	D	Cancer Acc Acc BLCA BLCA CL BLCA CL CL CL CL CL CL CL CL CL CL CL CL CL	0.0346 P value P value 0.021 0.021	23822(10.05125.3513)) 0 2005	ival
UCS UVM ACC BRCA BRCA BRCA CISIC CIGL ESCA GBM HINSC KICH KIRC LIGC LIGC LIGC LIGC LIGC LIGC UAD FRAD PRAD READ READ	0.1178 0.5113 P value P value 0.673 0.0673 0.0673 0.0673 0.0765 0.0673 0.0265 0.0673 0.0265 0.0273 0.0265 0.0265 0.0266 0.0265 0.0266 0.0265 0.0255 0.025	1.220(0,57173.3,3989) 1.32000,057053.023250 Maraart Ratio(955 c10) Sales/Sa	1977 12:52 30 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BLCA BLCA CLSC CIGAL DLBC ESCA CIGAL DLBC ESCA KIRC KIRC LIAD DLBC ESCA KIRC KIRC LIAD DLBC SCA STAD STAD STAD STAD STAD	0.0346 Disceit P value P value 0.0221 0.483 0.707 0.5709 0.8770 0.5709 0.8770 0.5709 0.4183 0.4199 0.4180 0.4388 0.4380 0.4388 0.4380 0.4388 0.4380 0.4388 0.43800 0.4380 0.4380 0.4380 0.48	23882(10.05125.3551)) 3 3 3 3 3 3 3 3 3 3 3 3 3	200571 2 3 4 5 Hazard I
UCS UVM ACC BLCA BRCA CAC CAC COAD DLBC COAD DLBC COAD DLBC COAD DLBC COAD LAN COAD LAN COAD LAN COAD LAN CAC CAC CAC CAC CAC CAC CAC CAC CAC C	0.1178 0.5113 P value 504 0.0673 0.2705 0.3801 0.2282 0.3280 0.2580 0.2570 0.25700 0.25700 0.25700 0.25700 0.25700 0.25700 0.25700 0.25700 0.25700000000000000000000000000000000000	1/200(057173.30490) 1/200(057053.02552) Inzero (Salado) 594 C10 Science (Salado) 594 C10 Sci	1137 125 20 40 50 6 Hazard Ratio	D	Caneer Acc Acc BLCA BLCA CCC CLCA CLCA CLCA CLCA CLCA	0.0346 P value P value O (502) P value (502) P value P	23822(1.045125.34511) 0 3282-6470-8450-747 120999-59095.64172) 1.1719(5.98072-64172) 1.1719(5.98072-64172) 1.1719(5.98072-64172) 1.1719(5.98072-64172) 1.1719(5.98072-64172) 0.99070-2472(1.34504) 0.99070-2472(1.34504) 0.99070-2451,132701) 1.99090-2454,132701 1.99090-2454,132701 1.99090-2454,132701 1.99090-2454,132701 1.99090-2454,132701 1.99090-2454,132701 1.99090-2454,132701 1.99090-2454,132701 1.99090-2454,13210 1.99090-2454,13210 1.99090-2454,13210 1.99090-2454,13210 1.99090-2454,13210 1.99090-2454,13210 1.99090-2454,53210 1.99090-2454,5321,94440 1.99090-2454,5322,34440 1.99090-2454,5322,34440	ival
UCS UVM ACC BLCA BCA CLIOL COAD CLIOC CLIOL COAD DLBC ESCA GBM HINSC CLIOL COAD CLIC LUIC LUIC LUIC LUIC LUIC LUIC LUIC	0.1178 0.5113 0.5113 P value 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.2765 0.0268 0.3203 0.3253 0.3253 0.3253 0.3253 0.3253 0.3253 0.3253 0.3253 0.3253 0.3553 0.03557 0.035777 0.035777 0.035777 0.0357777 0.03577777777777777777777777777777777777	1.220(0,57173.3,398) 1.32000,57053.02527) See_Specific St Set Rand Ratio 955 (1) Set Thyl C Add St A State Stat	U177 12.5 20 .00 .40 .50 6 Hazard Ratio	D	Cancer Acc. Acc. BLCA BLCA BLCA CIGL CIGL CIGL DLIC CIGL BLCC CIGL CIGL CIGL CIGL CIGL CIGL CIGL C	0.0346 Disceit P value 0.2621 0.6483 0.7070 0.3700 0.3700 0.3700 0.3430 0.3430 0.3430 0.3430 0.3430 0.3430 0.3430 0.3430 0.3430 0.3490 0.3450 0.3490 0.3450 0.3490 0.3400 0.34	23822(1.04512.53851)) 3 25 25 25 25 25 25 25 25 25 25	ival
UCS UVM ACC BLCA BRCA COAD COAD DLBC COAD COAD COAD COAD COAD COAD COAD COA	0.1178 0.5113 Prathe 0.0005 00	1.220(0,57173.3,3989) 1.32000,057053.02252) Maran Ratio(955.021) 1.302700,07300,20352 1.30270,07300,20352 1.30270,07300,20352 1.40977(0,97142,23654) 1.40977(0,97142,23654) 1.40977(0,97142,23654) 1.40977(0,97142,23654) 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.756651,0120,54025 0.45600,54025,12005 1.55701,000,4025,24020 1.55701,000,4025,24020 1.55701,0120,12015 0.55701,0120,0120 1.55701,0120,12015 0.55701,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120 1.55701,0120,0120,0120,0120 1.55701,0120,0120,0120,0120 1.55701,0120,0120,0120,0120 1.55701,0120,0120,0120,0120 1.55701,0120,0120,0120,0120 1.55701,0120,0120,0120,0120 1.55701,0120,0120,0120,0120,0120 1.55701,0120,0120,0120,0120,0120,0120,0120,0	III 125 20 40 50 6 Hazard Ratio	D	Cancer ACC BLCA BLCA BLCA CISC CIGL CIGL DLIC ESCA KIRC LICA LICA KIRC KIRC KIRC KIRC KIRC KIRC KIRC KIRC	0.0346 P value 0.2621 0.463 0.453 0.5709 0.5709 0.5709 0.5709 0.5536 0.5	23822(1.04512.53451)) 3 3 3 3 3 3 3 3 3 3 3 3 3	ival
UCS UVM ACC BLCA BBCA CESC CIOL COAD DLBC COAD COAD COAD COAD COAD COAD COAD COA	0.1178 0.5113 P value 504 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0095 0.0005 00	1/200(037133,3049) 1/200(037133,3049) 1/200(0353,02252) Inarad Raio(554,0215 Inarad Raio(554,0215 Inarad Raio(554,0215 Inarad Raio(554,0215 Inarad Raio(554,0215 Inarad Raio(554,0215 Inarad Raio(554,0215) Inarad Raio Raio(554,0215) Inarad Raio Raio(554,0215) Inarad Raio Raio Raio Raio Raio Raio Raio Raio	UITVIVAL		Caneer Acc Acc BLCA BLCA BLCA CCC CLGA CCC CLGA DLICC BLCA BLCA DLICC CLGA DLICC CLGA CLGA CLGA CLGA CLGA CLGA CLGA CL	0.0346 P value 0.2621 0.6483 0.6709 0.5709 0.5709 0.5536 0.5536 0.5459 0.3419 0.1407 0.1407 0.1407 0.0798 0.4462 0.3422 0.3422 0.3422 0.3422 0.3422 0.3526 0	23822(1.045125.34514) 0 3 3 3 3 3 3 3 3 3 3 3 3 3	ival
UCS UVM ACC BLCA CESC CEIOL COAD DLBC ESCA GBM HINSC CIDL BCC GGM KIRP LGG LLISC LUAC LUAC LUAC LUAC LUAC UNC SARC SARC SARC SARC SARC SARC SARC SAR	0.1178 0.5113 7 0.000 0.0005 0	1220(037173.3496) 1.32000.05705.320252) See_Specific S See_Specific S See_Specif S See_Specific S See_Specific S See_Spe	UITVIVAI	D	Cancer Acc. Acc. BLCA BLCA CLSC. CIGL DLIC CSC. KIRC LISC LISC LISC LISC LISC LISC LISC LIS	0.0346 P value P value 0.2621 0.2621 0.2621 0.2632 0.2632 0.2632 0.2632 0.2700 0.2740 0.3852 0.3855 0.3960 0.3474 0.3467 0.3788 0.3462 0.3555 0.27	23020(1001525.0351) 0 0 0 0 0 0 0 0 0 0 0 0 0	2 3 4 5 Hazard 1
UCS UVM ACC BLCA CESC CESC CESC CESC CESC CESC CESC CE	0.1178 0.5113 P ratue 5.0405 0.04050000000000	1.220(0,57173.3,3989) 1.32000,057053.02252) Maran Ratio(955.021) 1.32020(973062,0053,02252) 1.390270(973062,0053) 1.390270(973062,0053) 1.49077(0,97142,33664) 1.49077(0,97142,33664) 1.49077(0,97142,33664) 1.49077(0,97142,33664) 0.75665(110,2488,11,2600) 1.310270,072442,045070 1.310270,072442,045070 1.310270,072442,045070 1.310470,07442,045074 1.310470,07442,045074 0.415070,07442,045074 0.415070,07442,045074 0.415070,07442,045074 0.415070,07442,045074 0.415070,07442,045074 0.415070,07442,045074 0.415070,0740,01451,13507 1.59210,024411,55071 1.59210,024411,55071 1.595061,1702,21507 1.595	International Action of the second se	• •	Cancer ACC BLCA BLCA BLCA CISC CIGL CIGL DLBC ESCA KIRC LIGC LIGC LIGC LIGC STAD RTG STAD THCA UCC UCS	0.0346 P value 0.2621 0.6483 0.5709 0.5709 0.5709 0.5709 0.5709 0.5556 0.4596 0.4596 0.4596 0.4596 0.4596 0.4590 0.4460 0.4590 0.4670 0.4670 0.9326 0.0326 0.4590 0.4590 0.4670 0.9326 0.0356 0.0356 0.0356 0.0356 0.0360 0.0	2382(10.05125.3517)) 0 20 20 20 20 20 20 20 20 20	20071 2 3 4 5 Hazard

Figure 7 *SLC31A1* and prognosis of pan-cancer. (A) OS. (B) PFS. (C) DSS. (D) DFS. CI, confidence interval; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; OS, overall survival; PFS, progression-free survival; DSS, disease-specific survival; DFS, disease-free survival.

725

genetic alterations were negatively correlated with PFS in KIRC and READ patients (*Figure 7B*). *SLC31A1* genetic alterations were associated with DSS in ACC, KIRC, LGG, MESO, and SKCM patients. Among them, *SLC31A1* genetic alterations were positively correlated with DSS in ACC, LGG, MESO, and SKCM patients, and *SLC31A1* genetic alterations was negatively correlated with DSS in KIRC patients (*Figure 7C*). *Figure 7D* shows the relationship between cancer and DFS. Taken together, these results suggest that genetic alterations in *SLC31A1* are closely associated with the prognosis of patients with the abovementioned cancers.

TME, TMB, MSI, and drug sensitivity

Our study showed that SLC31A1 has a prognostic role in pan-cancer; thus, we further explored the expression of TME and SLC31A1 in different tumors. The results showed that the expression of SLC31A1 was positively correlated with the scores of stromal cells and immune cells in DLBC, LAML, LUAD, MESO, and SARC (Figure 8A), which suggest that the content of stromal cells or immune cells increases as the SLC31A1 expression level increases. However, the opposite results were found in ACC and thymoma (THYM). TMB refers to the rate of the base mutation in 1 million bases. MSI refers to the phenomenon of the emergence of new microsatellite alleles at the microsatellite site of a tumor due to gene insertion or deletion compared to normal tissue. This study found a clear association between SLC31A1 and TMB in ACC, BLCA, BRCA, COAD, LGG, LUAD, OV, READ, SARC, STAD, THYM, UCEC, and uterine carcinosarcoma (UCS) (Figure 8B). This study also found a clear association between SLC31A1 and MSI in CESC, COAD, DLBC, HNSC, LUSC, PRAD, SARC, STAD, THCA, and UCEC (*Figure 8C*). Finally, we used the CellMinerTM database to explore the potential correlation between drug sensitivity and SLC31A1 expression. The results showed that SLC31A1 expression was negatively correlated with the drug sensitivity of denileukin diftitox, entinostat, and alectinib, but positively correlated with (+)-BET bromodomain inhibitor (JQ1) (Figure 8D). In summary, SLC31A1 may be associated with chemotherapy resistance to certain chemotherapy drugs.

Methylation levels of SLC31A1 in pan-cancer

We explored the methylation levels of SLC31A1 in various

cancers using the UALCAN database. The results showed that *SLC31A1* methylation levels were highly expressed in LUSC and READ. Conversely, *SLC31A1* methylation levels were lowly expressed in HNSC, KIRP, LIHC, PRAD, and UCEC (*Figure 9*).

Correlation between SLC31A1 expression and the immune response

We used the TIMER2.0 database to explore the correlation between immune infiltrating cells and SLC31A1 expression using TCGA database. We found that SLC31A1 expression was positively correlated with the immune infiltration of B cells in PAAD and PCPG. Conversely, it was negatively correlated with the immune infiltration of B cells in BRCA-Basal, DLBC, MESO, and TGCT (Figure 10A). Meanwhile, SLC31A1 expression was positively correlated with the immune infiltration of cluster of differentiation (CD)4⁺ T cells in COAD and DLBC. Conversely, it was negatively correlated with the immune infiltration of CD4⁺ T cells in CHOL and GBM (Figure 10B). Further, SLC31A1 expression was positively correlated with the immune infiltration of CD8⁺ T cells in DLBC, LGG, PAAD, and UVM. Conversely, it was negatively correlated with the immune infiltration of CD8⁺ T cells in ACC and ESCA (Figure 10C). Further, SLC31A1 expression was positively correlated with the immune infiltration of natural killer (NK) cell in BLCA, COAD, DLBC, LIHC, and TGCT. Conversely, it was negatively correlated with the immune infiltration of NK cells in KIRC, KIRP, LGG, MESO, SKCM, and THCA (Figure 10D). In addition, SLC31A1 expression was positively correlated with the immune infiltration of dendritic cells (DCs) in BRCA, COAD, DLBC, HNSC-human papillomavirus (HPV)⁺, KIRC, KIRP, LGG, LUAD, PAAD, PRAD, SKCM, and TGCT. Conversely, it negatively correlated with the immune infiltration of DCs in ESCA and LIHC (Figure 10E). Finally, SLC31A1 expression was positively correlated with the immune infiltration of regulatory T cells (Tregs) in BLCA, CESC, ESCA, LGG, LUSC, PAAD, SKCM, TGCT, and UVM. Conversely, it was negatively correlated with the immune infiltration of Tregs cells in ACC, DLBC, KIRC, and PCPG (Figure 10F). Further, Figure S2 sets out the correlations between SLC31A1 expression and neutrophils, monocytes, macrophages, mast cells, cancer-associated fibroblasts, common lymphoid progenitor cells, endothelial cells, common myeloid progenitor cells, the immune infiltration of eosinophils,



Figure 8 Relationship between *SLC31A1* and the tumor microenvironment, tumor mutation burden, microsatellite instability, and drug sensitivity. (A) Tumor microenvironment. (B) Tumor mutation burden. (C) Microsatellite instability. (D) Drug sensitivity. *, P<0.05; **, P<0.01; ***, P<0.001. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; *SLC31A1*, solute carrier family 31 (copper transporter), member 1.

Zhang et al. Cuprotosis-associated gene SLC31A1



Figure 9 *SLC31A1* methylation levels of different cancers in the UALCAN database. *, P<0.05; **, P<0.01; ****, P<0.0001. TCGA, The Cancer Genome Atlas; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; HNSC, head and neck squamous cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; UALCAN, University of Alabama at Birmingham CANcer.

granulocyte-monocyte progenitor cells, hematopoietic stem cells, follicular helper T cells, gamma delta T cells, NK T cells, and myeloid-derived suppressor cells. The above study indicates the potential significance of SLC31A1 in the immune infiltration of the TME.

Expression of SLC31A1 at the single-cell level

The CancerSEA database was used to study the expression levels of *SLC31A1* at the single-cell level to further explore the role of *SLC31A1* in bio-functional states. *SLC31A1* expression in UVM was negatively correlated with DNA damage, DNA repair, and apoptosis. The expression level of *SLC31A1* in retinoblastoma (RB) was positively correlated with angiogenesis and differentiation. The expression of *SLC31A1* in OV was positively correlated with quiescence (*Figure 11A*). Further, *Figure 11B* shows the correlations between *SLC31A1* expression and DNA repair in UVM, angiogenesis in RB, and quiescence in OV. Finally, *Figure 11C* shows the distribution of SLC31A1 expression at the single-cell level in UVM, RB, and OV. Taken together, it appears that *SLC31A1* could potentially be critical in the regulation of biological functions in cancer.

Enrichment analysis of SLC31A1-related genes

We used bioGRID to investigate the SLC31A1-interacting

biomarkers (*Figure 12A*). Meanwhile, the top 100 genes associated with *SLC31A1* were downloaded from the GEPIA 2.0 database (Table S1). The expression levels of *SLC31A1* were correlated with CHGB, CYB561, DBH, EML5, PHOX2B, and TBX20 in pan-cancer (*Figure 12B*). Further, as the heat map in *Figure 12C* shows, *SLC31A1* was positively correlated with the above genes in most cancers. Finally, the Gene Ontology (GO) and KEGG enrichment analysis indicated that *SLC31A1*-related genes were mainly enriched in the mitochondrial matrix and coated vesicles (*Figure 12D*).

Validation of SLC31A1 expression

To verify the expression of *SLC31A1* in pan-cancer, we explored it at the messenger RNA (mRNA) and protein levels in liver cancer cells (L-O2, SMMC-7721, HUh7, H-97, and HepG2), gastric cancer cells (GES-1, HGC-27, AGS, and MKN-54,) and colon cancer cells (NCM460, RKO, LoVo, and DLD-1) using both RT-qPCR and WB. We found that at the mRNA level, the liver, gastric, and colon cancer cells were lowly, highly, and lowly expressed, respectively, compared with their corresponding normal cells (*Figure 13A-13C*). Next, our results showed that hepatocellular carcinoma and gastric carcinoma cells were highly expressed at the protein level (except SMMC-7721) compared with their corresponding normal cells.



Figure 10 Correlation analysis of *SLC31A1* gene expression with multiple immune cells based on TIMER2.0 database. (A) B cells. (B) CD4⁺ T cells. (C) CD8⁺ T cell. (D) NK cells. (E) DC. (F) Tregs. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; NK, natural killer; DC, dendritic cell; Tregs, regulatory T cells; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; TIMER, Tumor Immune Estimation Resource.



Figure 11 *SLC31A1* expression levels at the single-cell sequencing level. (A,B) CancerSEA database shows the correlation of *SLC31A1* expression with multiple biological functions in pan-cancer. (C) t-SNE plots showing the distribution of *SLC31A1* in UVM, RB, and OV at the single-cell level. *, P<0.05; **, P<0.01; ***, P<0.001. ALL, acute lymphoblastic leukemia; AML, acute myelocytic leukemia; CML, chronic myelogenous leukemia; BRCA, breast invasive carcinoma; AST, aspartate transaminase; GBM, glioblastoma multiforme; HGG, human gamma globulin; ODG, ovarian dysgenesis; HNSCC, head and neck squamous cell carcinoma; RCC, renal cell carcinoma; LUAD, lung adenocarcinoma; NSCLC, non-small cell lung cancer; OV, ovarian serous cystadenocarcinoma; MEL, mouse erythroleukemia; RB, retinoblastoma; UVM, uveal melanoma; EMT, epithelial-mesenchymal transition; t-SNE, t-distributed stochastic neighbor embedding; *SLC31A1*, solute carrier family 31 (copper transporter), member 1.

Conversely, the colon cancer cells were lowly expressed at the protein level (*Figure 13D-13F*). *Figure 13G-13I* provides a quantitative graph of protein expression.

Discussion

In this study, we explored *SLC31A1* expression, prognosis, mutation, methylation, and the immune response, and conducted a single-cell assessment, and an enrichment analysis in cancer using a series of bioinformatics online database approaches. Finally, RT-qPCR and WB were used to validate the differentially expressed significant hepatocellular carcinomas, gastric cancer, and colon cancer. The results showed that as a *CTR*, *SLC31A1* has an

important effect on the human body.

Copper is an essential trace element for life. All living things require copper to function properly and to maintain homeostasis; thus, maintaining the proper level of copper is crucial. Copper deficiency impairs the activity of copper-binding enzymes, and copper buildup causes cell death (22). Tsvetkov *et al.* recently demonstrated that copper alone, as opposed to copper ion clusters, is harmful to cells (8). Unlike other known types of death, such as apoptosis, ferroptosis, and necroptosis, cuproptosis is a completely new type of cell death (8). Instead of making adenosine triphosphate (ATP), it depends on mitochondrial respiration ATP (8). One of the key elements in maintaining intracellular copper concentration is the copper importer

730



© Translational Cancer Research. All rights reserved.

Transl Cancer Res 2024;13(2):714-737 | https://dx.doi.org/10.21037/tcr-23-1308



Figure 12 Enrichment analysis of *SLC31A1*-associated genes in pan-cancer. (A) Interaction network of *SLC31A1*-associated biomarkers derived from the BioGRID database. (B) GEPIA2.0 showed that *SLC31A1* expression was positively correlated with CHGB, CYB561, DBH, EML5, PHOX2B, and TBX20 genes. (C) Heat map showing that *SLC31A1* expression was positively correlated with six genes (i.e., CHGB, CYB561, DBH, EML5, PHOX2B, and TBX20). (D) GO/KEGG enrichment analysis of the *SLC31A1*-related genes. *SLC31A1*, solute carrier family 31 (copper transporter), member 1; TPM, transcripts per million; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; CAA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma; TCA, tricarboxylic acid; GEPIA, Gene Expression Profiling Interactive Analysis; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.

(*SCL31A1*). *SCL31A1* encodes CTR1, which is essential for the uptake of high-affinity copper (23).

Our study showed that *SLC31A1* is expressed in most cancers. Among them, *SLC31A1* was highly expressed in BLCA, BRCA, CESC, COAD, DLBC, ESCA, GBM, LGG, HNSC, PAAD, PCPG, READ, STAD, and UCEC.

Conversely, *SLC31A1* was lowly expressed in CHOL, KIRC, KIRP, LAML, LIHC, LUAD, LUSC, PRAD, and THCA. Barresi *et al.* reported high expressions of *SLC31A1* in COAD (24). Li *et al.* showed that *SLC31A1* was highly expressed in BRCA, which validates our findings (25). Jiang *et al.* showed that *SLC31A1* was highly



Figure 13 *SLC31A1* expression validation results. (A-C) Expression of *SLC31A1* at the mRNA level in liver, gastric, and colon cancer cells. (D-F) Expression of *SLC31A1* at the protein level in liver, gastric, and colon cancer cells. (G-I) Quantification of protein level expression. *, P<0.05; **, P<0.01; ****, P<0.001; ****, P<0.001. *SLC31A1*, solute carrier family 31 (copper transporter), member 1; mRNA, messenger RNA.

expressed in HNSC epithelial cells, which also validates our findings (26). Song *et al.* showed that the suppression of the *SLC31A1* gene, which is responsible for encoding the primary transmembrane CTR1, effectively diminishes the malignancy of PAAD through the down-regulation of intracellular copper levels. These findings align with our own research outcomes (27). In summary, *SLC31A1* is expressed in most cancers.

Our study found that high *SLC31A1* expression was associated with good OS in KIRC, while the opposite was true in ACC, BRCA, LGG, MESO, and SKCM. High expression levels of *SLC31A1* were associated with good DFS in KIRC and STAD, but the opposite was true in ACC, LGG, and MESO. Lv *et al.* showed that *SLC31A1* up-regulation has value in predicting the prognosis of SKCM patients. This is consistent with our findings (28). Li *et al.* found that *SLC31A1* may be a promising diagnostic/ prognostic biomarker and predictor of the drug response in breast cancer patients (25).

Further, we evaluated the genetic alterations of *SLC31A1* in pan-cancer. The results showed that the amplification frequency of *SLC31A1* was the highest in ACC, and its mutation types mainly included missense mutations, truncating mutations, splicing mutations, and fusion. The truncating mutation, S105Y, has the potential to be a putative cancer driver. We also presented the 3D structure

of S105Y.

DNA methylation is known to be abnormal in all forms of cancer (29). Normal cells may be transformed by the onset of driver mutations and then consequently undergo *de novo* and demethylation processes, thereby initiating a series of programmed changes in gene expression. Alternatively, a subpopulation of normal cells that may have undergone methylation changes, possibly due to senescence, may be preferred targets for oncogenic transformation (30,31). Our study found that the methylation level of SLC31A1 was highly expressed in LUSC and READ; however, it was lowly expressed in HNSC, KIRP, LIHC, PRAD, and UCEC.

Adaptive immune responses may be triggered by innate immune cells, and research into and the development of immunotherapy will be aided by knowledge of the internal workings of cancer (32,33). According to Schalper et al. and Bremnes et al. (34,35), type I immune responses are typically associated with CD8⁺ T cells and T cells triggered by CD4⁺ type 1 T helper cells, and they are associated with a positive prognosis for lung cancer patients. According to Marshall et al. (36), type 2 T helper cells, type 17 T helper cells, and Foxp3⁺ Tregs are frequently linked to poor tumor growth and prognosis. Sautès-Fridman et al. (37) showed that tumor-infiltrating B lymphocytes elicit a strong and advantageous immune response in the majority of solid tumors. According to Petitprez et al. (38), the B-cell count is the best indicator of long-term survival in soft tissue sarcomata. Our study found that SLC31A1 expression was positively correlated with the immune infiltration of B cells in PAAD and PCPG. However, the immune infiltration of B cells was negatively correlated with BRCA-basal, DLBC, MESO, and TGCT. SLC31A1 expression was positively correlated with the CD4⁺ immune infiltration of T cells in COAD and DLBC. However, it was negatively correlated with the immune infiltration of CD4⁺ in T cells in CHOL and GBM. SLC31A1 expression was positively correlated with the CD8⁺ immune infiltration of T cells in DLBC, LGG, PAAD, and UVM. However, it was negatively correlated with the T cell CD8⁺ immune infiltration in ACC and ESCA. SLC31A1 expression was positively correlated with the immune infiltration of NK cells in BLCA, COAD, DLBC, LIHC, and TGCT. Conversely, it was negatively correlated with the immune infiltration of NK cells in KIRC, KIRP, LGG, MESO, SKCM, and THCA. SLC31A1 expression was positively correlated with the immune infiltration of DCs in BRCA, COAD, DLBC, HNSC-HPV⁺, KIRC, KIRP, LGG, LUAD, PAAD,

PRAD, SKCM, and TGCT. Conversely, it was negatively correlated with the immune infiltration of DCs in ESCA and LIHC. Finally, *SLC31A1* expression was positively correlated with the immune infiltration of Tregs in BLCA, CESC, ESCA, LGG, LUSC, PAAD, SKCM, TGCT, and UVM. Conversely, it was negatively correlated with the immune infiltration of Tregs cells in ACC, DLBC, KIRC, and PCPG. In summary, our study further elucidated the TME of pan-cancer.

Further, we investigated the single-cell level expression of SLC31A1 and conducted an enrichment analysis of the SLC31A1-related genes. We found that SLC31A1 plays an important role in UVM, RB, and OV, etc., which helps us explore further the role of SLC31A1 in tumors. The SLC31A1 enrichment analysis revealed that the SLC31A1related genes were mainly enriched in the mitochondrial matrix and coated vesicles, which gives us a better understanding of its mechanism. It has been demonstrated that SLC31A1 affects intracellular (Cuprum) Cu²⁺ levels by acting as a copper importer. High cell membrane trace elements and a higher threshold level of mitochondrial membrane potential ($\Delta \Psi m$) are required for trace element entrance into the mitochondrial matrix. Due to the use of all ATP, the increase of trace elements in the mitochondrial matrix causes a decrease in ATP levels. Ca²⁺ inflow into the mitochondrial matrix is mostly regulated by the (Natrium) Na⁺/Ca²⁺ exchanger (NCX) and the mitochondrial calcium monomer (MCU).

Finally, we used RT-qPCR and WB to verify the expression of SLC31A1 in the pan-cancer. The RT-qPCR results showed that the expression of SLC31A1 in liver and gastric cancers was consistent with our predicted results, but in colon cancer the expression was opposite to our predicted results. This could be caused by the heterogeneity between cells, as our prediction results came from tissue samples in a largely open database, and could also be caused by differences in tissue sample volume or tissue and cellular levels. Based on the above issues, we further validated the protein expression levels in liver, gastric, and colon cancer cells using the WB technique. Contrary to our RT-qPCR results and bioinformatics predictions, the results showed high SLC31A1 expression in liver cancer cells (except SMMC-7721), which may be due to cell-to-cell differences; thus, further validation of its expression in tissues will be necessary in future studies.

The present study observed contrasting outcomes pertaining to *SLC31A1* expression at both the mRNA and protein levels in hepatocellular carcinoma cells, which

might be due to the following factors: (I) given that this study serves as a fundamental validation of a bioinformatics analysis, it is plausible that incongruity exists in the expression of this gene at both the transcript and protein levels; (II) intriguingly, this discrepancy could potentially be attributed to a multitude of transcriptome or protein-level modifications, which will subsequently be explored as the next avenue of investigation in our research; (III) in light of the absence of evidence regarding the expression of the SLC31A1 gene in hepatocellular carcinoma in the previous relevant literature, we intend to delve deeper into this finding by conducting further investigations; (IV) despite the low mRNA level, the protein level adequately reflects the clinical significance of SLC31A1, and its elevated expression is strongly associated with clinical prognosis. The expression of gastric cancer cells at the protein level was in full agreement with our RT-qPCR results and bioinformatics predictions, which further improved the reliability of our study. The expression of colon cancer cells at the protein level was consistent with our RT-qPCR results, but contrary to the bioinformatics predictions. This may be because our predictions were based on tissue samples from the database, which may have some differences among the cells. Therefore, we should have further investigated the expression of SLC31A1 at the tissue level, but we lacked the conditions to validate it in tissues, which is the biggest limitation of our study.

Conclusions

In summary, this study analyzed the expression level, methylation level, gene mutation, patient survival prognosis, and immune cell infiltration of the cuprotosis-related gene *SLC31A1* in pan-cancer. We also analyzed *SLC31A1* at the single-cell transcriptional sequencing level and explored its different biological functions. *SLC31A1* may mediate the prognosis of tumor patients by regulating tumor energy metabolism processes, coating vesicles, and affecting the immune microenvironment, and may be a potential genetic, immune, and energy-metabolic-dependent predictive target.

Acknowledgments

We would like to thank the staff at the Key Laboratory of Molecular Diagnostics and Precision Medicine for Surgical Oncology in Gansu Province, and the General Surgery, Clinical Medical Center of Gansu Provincial Hospital for their contributions. Funding: This work was supported by grants from the National Natural Science Foundation of China (82360498), Gansu Joint Scientific Research Fund Major Project under Grant (23JRRA1537), Gansu Provincial People's Hospital Key Research Fund (20GSSY1-11), 2021 Central-Guided Local Science and Technology Development Fund (ZYYDDFFZZJ-1), Key Talent Project of Gansu Province of the Organization Department of Gansu Provincial Party Committee (2020RCXM076), Gansu Provincial Youth Science and Technology Fund Program (21JR7RA642), Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences (21GSSYC-2), Gansu Key Laboratory of Molecular Diagnosis and Precision Treatment of Surgical Tumors (18JR2RA033), Gansu Provincial People's Hospital Excellent Master/PhD Student Incubation Program Project Fund (22GSSYD-19), Natural Science Foundation of Gansu Province (21JR11RA186), National Health Care Commission Key Laboratory of Gastrointestinal Tumor Diagnosis and Treatment Open Fund (NHCDP2022022), and Key Project of Science and Technology Innovation Platform Fund of Gansu Provincial People's Hospital (21gssya-4).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1308/rc

Peer Review File: Available at https://tcr.amegroups.com/ article/view/10.21037/tcr-23-1308/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-23-1308/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the

original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

- The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Oncol 2022;23:27-52.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209-49.
- Gersten O, Barbieri M. Evaluation of the Cancer Transition Theory in the US, Select European Nations, and Japan by Investigating Mortality of Infectious- and Noninfectious-Related Cancers, 1950-2018. JAMA Netw Open 2021;4:e215322.
- Marusyk A, Almendro V, Polyak K. Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-34.
- Kather JN, Suarez-Carmona M, Charoentong P, et al. Topography of cancer-associated immune cells in human solid tumors. Elife 2018;7:e36967.
- Tarantino P, Mazzarella L, Marra A, et al. The evolving paradigm of biomarker actionability: Histologyagnosticism as a spectrum, rather than a binary quality. Cancer Treat Rev 2021;94:102169.
- Ahmed R, Augustine R, Valera E, et al. Spatial mapping of cancer tissues by OMICS technologies. Biochim Biophys Acta Rev Cancer 2022;1877:188663.
- 8. Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 2022;375:1254-61.
- Jiang Y, Huo Z, Qi X, et al. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes. Nanomedicine (Lond) 2022;17:303-24.
- Kim H, Wu X, Lee J. SLC31 (CTR) family of copper transporters in health and disease. Mol Aspects Med 2013;34:561-70.
- 11. Eisses JF, Kaplan JH. The mechanism of copper uptake mediated by human CTR1: a mutational analysis. J Biol Chem 2005;280:37159-68.
- Maryon EB, Molloy SA, Ivy K, et al. Rate and regulation of copper transport by human copper transporter 1 (hCTR1). J Biol Chem 2013;288:18035-46.
- 13. Aupič J, Lapenta F, Janoš P, et al. Intrinsically

disordered ectodomain modulates ion permeation through a metal transporter. Proc Natl Acad Sci U S A 2022;119:e2214602119.

- Wei J, Wang S, Zhu H, et al. Hepatic depletion of nucleolar protein mDEF causes excessive mitochondrial copper accumulation associated with p53 and NRF1 activation. iScience 2023;26:107220.
- Das A, Ash D, Fouda AY, et al. Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis. Nat Cell Biol 2022;24:35-50.
- Brady DC, Crowe MS, Turski ML, et al. Copper is required for oncogenic BRAF signalling and tumorigenesis. Nature 2014;509:492-6.
- Chen GF, Sudhahar V, Youn SW, et al. Copper Transport Protein Antioxidant-1 Promotes Inflammatory Neovascularization via Chaperone and Transcription Factor Function. Sci Rep 2015;5:14780.
- Grasso M, Bond GJ, Kim YJ, et al. The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation. J Biol Chem 2021;297:101314.
- Logeman BL, Wood LK, Lee J, et al. Gene duplication and neo-functionalization in the evolutionary and functional divergence of the metazoan copper transporters Ctr1 and Ctr2. J Biol Chem 2017;292:11531-46.
- Wezynfeld NE, Vileno B, Faller P. Cu(II) Binding to the N-Terminal Model Peptide of the Human Ctr2 Transporter at Lysosomal and Extracellular pH. Inorg Chem 2019;58:7488-98.
- Møller LB, Petersen C, Lund C, et al. Characterization of the hCTR1 gene: genomic organization, functional expression, and identification of a highly homologous processed gene. Gene 2000;257:13-22.
- 22. Kahlson MA, Dixon SJ. Copper-induced cell death. Science 2022;375:1231-2.
- Lutsenko S. Human copper homeostasis: a network of interconnected pathways. Curr Opin Chem Biol 2010;14:211-7.
- 24. Barresi V, Trovato-Salinaro A, Spampinato G, et al. Transcriptome analysis of copper homeostasis genes reveals coordinated upregulation of SLC31A1,SCO1, and COX11 in colorectal cancer. FEBS Open Bio 2016;6:794-806.
- 25. Li X, Ma Z, Mei L. Cuproptosis-related gene SLC31A1 is a potential predictor for diagnosis, prognosis and therapeutic response of breast cancer. Am J Cancer Res 2022;12:3561-80.
- 26. Jiang X, Ke J, Jia L, et al. A novel cuproptosis-related gene signature of prognosis and immune microenvironment in

head and neck squamous cell carcinoma cancer. J Cancer Res Clin Oncol 2023;149:203-18.

- 27. Song G, Dong H, Ma D, et al. Tetrahedral Framework Nucleic Acid Delivered RNA Therapeutics Significantly Attenuate Pancreatic Cancer Progression via Inhibition of CTR1-Dependent Copper Absorption. ACS Appl Mater Interfaces 2021;13:46334-42.
- Lv H, Liu X, Zeng X, et al. Comprehensive Analysis of Cuproptosis-Related Genes in Immune Infiltration and Prognosis in Melanoma. Front Pharmacol 2022;13:930041.
- Klutstein M, Nejman D, Greenfield R, et al. DNA Methylation in Cancer and Aging. Cancer Res 2016;76:3446-50.
- Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest 2014;124:24-9.
- Easwaran H, Tsai HC, Baylin SB. Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014;54:716-27.
- 32. Kishi M, Asgarova A, Desterke C, et al. Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy. Front Med (Lausanne) 2021;8:729018.

Cite this article as: Zhang G, Wang N, Ma S, Tao P, Cai H. Comprehensive analysis of the effects of the cuprotosisassociated gene *SLC31A1* on patient prognosis and tumor microenvironment in human cancer. Transl Cancer Res 2024;13(2):714-737. doi: 10.21037/tcr-23-1308

- Shen P, Deng X, Hu Z, et al. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. Front Med (Lausanne) 2021;8:762247.
- 34. Schalper KA, Brown J, Carvajal-Hausdorf D, et al. Objective measurement and clinical significance of TILs in non-small cell lung cancer. J Natl Cancer Inst 2015;107:dju435.
- Bremnes RM, Busund LT, Kilvær TL, et al. The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. J Thorac Oncol 2016;11:789-800.
- Marshall EA, Ng KW, Kung SH, et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer 2016;15:67.
- Sautès-Fridman C, Lawand M, Giraldo NA, et al. Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention. Front Immunol 2016;7:407.
- Petitprez F, de Reyniès A, Keung EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 2020;577:556-60.

Normal Lung

LUSC

Figure S1 *SLC31A1* expression in the UACLAN and HPA databases. *, P<0.05; ****, P<0.0001. TCGA, The Cancer Genome Atlas; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; KIRC, kidney renal clear cell carcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; THCA, thyroid carcinoma; UALCAN, University of Alabama at Birmingham CANcer; HPA, Human Protein Atlas.

Figure S2 Correlation analysis of *SLC31A1* gene expression with multiple immune cells based on TIMER2.0 database. NK, natural killer; *SLC31A1*, solute carrier family 31 (copper transporter), member 1; TIMER, Tumor Immune Estimation Resource.

Table S1 Top 100 genes associated with SLC31A1 in the GEPIA 2.0 database

Gene symbol	Gene ID	PCC
CYB561	ENSG0000008283.15	0.54
CHGB	ENSG0000089199.9	0.53
EML5	ENSG00000165521.15	0.53
DBH	ENSG00000123454.10	0.52
PHOX2B	ENSG00000109132.6	0.51
TBX20	ENSG0000164532 10	0.5
	ENCC00000148248 12	0.5
	ENGC00000140240.10	0.0
SLC6A2	ENSG00000103546.18	0.49
RP11-269G24.4	ENSG00000265282.1	0.49
LINC00682	ENSG00000245870.2	0.49
GCH1	ENSG00000131979.18	0.49
MAB21L1	ENSG00000180660.7	0.49
CHGA	ENSG00000100604.12	0.48
CHRNA3	ENSG0000080644.15	0.48
ТН	ENSG00000180176.14	0.48
RP11-415l12.2	ENSG00000255583.2	0.47
KCNG4	ENSG0000168418 7	0.47
	ENSC00000227125.8	0.47
	EN3G00000237123.8	0.47
CHRNB4	ENSG0000011/9/1.11	0.47
C18orf42	ENSG00000231824.3	0.46
RIMBP2	ENSG0000060709.13	0.46
RP11-662M24.2	ENSG00000256725.1	0.46
DRD2	ENSG00000149295.13	0.46
HAND2	ENSG00000164107.8	0.45
RP11-561B11.6	ENSG00000259017.1	0.45
DDC	ENSG00000132437.17	0.45
SLC18A1	ENSG0000036565.14	0.45
TTC8	ENSG00000165533 18	0.45
	ENSC0000169618 6	0.45
	ENISCO000100014144	0.44
	ENOGUUUUU102241.11	U.44
КР11-124О11.1	ENSG00000234944.1	0.44
RP11-481F24.3	ENSG00000278928.1	0.44
RP11-227F19.1	ENSG00000250467.1	0.43
DGKK	ENSG00000274588.1	0.43
SYT4	ENSG00000132872.11	0.43
TLX2	ENSG00000115297.10	0.43
SEZ6L2	ENSG00000174938.14	0.43
MRAP2	ENSG00000135324 5	0.43
	ENSC00000100102126 15	0.40
	ENSG00000122120.15	0.43
CAMK4	ENSG00000152495.10	0.43
HACD3	ENSG00000074696.12	0.43
PTPRN2	ENSG00000155093.17	0.43
UBQLN1	ENSG00000135018.13	0.43
CFAP20	ENSG0000070761.7	0.43
SCG2	ENSG00000171951.4	0.42
SLC18A2	ENSG00000165646.11	0.42
RP11-976B16.1	ENSG00000274492.1	0.42
EBLEC1	ENSG0000068912 13	0.42
EAM162A	ENSC00000142240.6	0.42
FAIVIT03A	ENSG00000143340.0	0.42
AIP6V1G1	ENSG00000136888.6	0.42
L1CAM	ENSG00000198910.12	0.42
COG5	ENSG00000164597.13	0.41
PHOX2A	ENSG00000165462.5	0.41
CDK5R2	ENSG00000171450.5	0.41
DSTNP5	ENSG00000236681.1	0.41
TMX4	ENSG00000125827.8	0.41
RBM18	ENSG00000119446.13	0.41
DNAJC3	ENSG00000102580.14	0.4
BP11-42901 1	ENSG00000263317 1	0.4
DD11 150N11 2	ENSC00000266757.1	0.4
	EN3G00000250757.1	0.4
RAB3C	ENSG00000152932.7	0.4
RP11-17A4.2	ENSG00000254254.5	0.4
JKAMP	ENSG00000050130.17	0.4
ALG2	ENSG00000119523.9	0.4
TMEM63C	ENSG00000165548.10	0.4
LL09NC01-254D11.1	ENSG00000261018.1	0.39
RET	ENSG00000165731.17	0.39
FAIM2	ENSG00000135472.8	0.39
G3BP2	ENSG00000138757.14	0.39
ARFGEF3	ENSG00000112379.8	0.39
GPR107	ENSG00000148358 19	0.39
FAM163B		0.30
RD11 01/D5 1	ENISCO000020007 0	0.00
		0.09
SPUCK3	ENSGUUUUU196104.10	0.39
CALM2	ENSG00000143933.16	0.39
YIPF6	ENSG00000181704.11	0.38
DRGX	ENSG00000165606.8	0.38
QDPR	ENSG00000151552.11	0.38
SLC35D3	ENSG00000182747.4	0.38
SAR1B	ENSG00000152700.13	0.38
HAND1	ENSG00000113196.2	0.38
PRLHR	ENSG00000119973.4	0.38
DNAJC25	ENSG00000059769.19	0.38
SHF	ENSG00000138606 19	0.38
CTC-340D7 1	ENISCO0000240225 1	0.35
		0.00
	ENGGUUUUU219545.9	0.38
IM9SF2	ENSG00000125304.8	0.38
RP5-967N21.2	ENSG00000215589.3	0.38
SHC1	ENSG00000160691.18	0.38
INSM2	ENSG00000168348.3	0.38
VPS33A	ENSG00000139719.9	0.38
BEGAIN	ENSG00000183092.15	0.38
RP11-475B2.1	ENSG00000261672.1	0.38
CELF3	ENSG00000159409.14	0.37
СНИК	ENSG00000213341 10	0.37
	ENSG0000023312 17	0.37
RD11 10M5 0	ENISCO00000000075	0.07
nr i 1-12M5.3	ENOGO000229407.5	U.37
GPR22	ENSG00000172209.5	0.37
YIPF5	ENSG00000145817.16	0.37
INIP	ENSG00000148153.13	0.37

SLC31A1, solute carrier family 31 (copper transporter), member 1; GEPIA, Gene Expression Profiling Interactive Analysis; PCC, preclinical candidate compounds.

© Translational Cancer Research. All rights reserved.

https://dx.doi.org/10.21037/tcr-23-1308